425 related articles for article (PubMed ID: 29388678)
21. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
22. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
[TBL] [Abstract][Full Text] [Related]
23. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose.
Oedingen C; Scholz S; Razum O
Thromb Res; 2018 May; 165():68-78. PubMed ID: 29573722
[TBL] [Abstract][Full Text] [Related]
24. Hormonal contraception and risk of venous thromboembolism: national follow-up study.
Lidegaard Ø; Løkkegaard E; Svendsen AL; Agger C
BMJ; 2009 Aug; 339():b2890. PubMed ID: 19679613
[TBL] [Abstract][Full Text] [Related]
25. Combined hormonal contraception and venous thromboembolism.
Martínez F; Avecilla A
Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006
[TBL] [Abstract][Full Text] [Related]
26. Venous Thromboembolic Risk of Estradiol Valerate-Dienogest Compared with Ethinyl Estradiol-Levonorgestrel Combined Oral Contraceptives.
Bauerfeind A; von Stockum S; Boehnke T; Heinemann K
Obstet Gynecol; 2024 Mar; 143(3):431-434. PubMed ID: 38227942
[TBL] [Abstract][Full Text] [Related]
27. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
28. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.
Morimont L; Haguet H; Dogné JM; Gaspard U; Douxfils J
Front Endocrinol (Lausanne); 2021; 12():769187. PubMed ID: 34956081
[TBL] [Abstract][Full Text] [Related]
29. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke.
Roach RE; Helmerhorst FM; Lijfering WM; Stijnen T; Algra A; Dekkers OM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011054. PubMed ID: 26310586
[TBL] [Abstract][Full Text] [Related]
30. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
31. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
Dinger J; Do Minh T; Heinemann K
Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
[TBL] [Abstract][Full Text] [Related]
32. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review.
Tepper NK; Phillips SJ; Kapp N; Gaffield ME; Curtis KM
Contraception; 2016 Sep; 94(3):262-74. PubMed ID: 26002804
[TBL] [Abstract][Full Text] [Related]
33. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies.
Shapiro S; Dinger J
J Fam Plann Reprod Health Care; 2010 Jan; 36(1):33-8. PubMed ID: 20067670
[TBL] [Abstract][Full Text] [Related]
34. Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over.
Mackie IJ; Piegsa K; Furs SA; Johnson J; Bounds W; Machin SJ; Guillebaud J
Br J Haematol; 2001 Jun; 113(4):898-904. PubMed ID: 11442481
[TBL] [Abstract][Full Text] [Related]
35. Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.
Rott H
Hamostaseologie; 2019 Feb; 39(1):42-48. PubMed ID: 30669160
[TBL] [Abstract][Full Text] [Related]
36. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
Plu-Bureau G; Sabbagh E; Hugon-Rodin J
Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
[TBL] [Abstract][Full Text] [Related]
37. Systemic hormonal contraception and risk of venous thromboembolism.
Heikinheimo O; Toffol E; Partonen T; But A; Latvala A; Haukka J
Acta Obstet Gynecol Scand; 2022 Aug; 101(8):846-855. PubMed ID: 35633036
[TBL] [Abstract][Full Text] [Related]
38. Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis.
Bateson D; Butcher BE; Donovan C; Farrell L; Kovacs G; Mezzini T; Raynes-Greenow C; Pecoraro G; Read C; Baber R
Aust Fam Physician; 2016; 45(1):59-64. PubMed ID: 27051991
[TBL] [Abstract][Full Text] [Related]
39. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
40. Contraception, venous thrombosis and biological plausability.
Rott H
Minerva Med; 2013 Apr; 104(2):161-7. PubMed ID: 23514992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
